JP2023510350A5 - - Google Patents
Info
- Publication number
- JP2023510350A5 JP2023510350A5 JP2022542336A JP2022542336A JP2023510350A5 JP 2023510350 A5 JP2023510350 A5 JP 2023510350A5 JP 2022542336 A JP2022542336 A JP 2022542336A JP 2022542336 A JP2022542336 A JP 2022542336A JP 2023510350 A5 JP2023510350 A5 JP 2023510350A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- complex according
- exon
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025172493A JP2026012197A (ja) | 2020-01-10 | 2025-10-14 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959796P | 2020-01-10 | 2020-01-10 | |
| US62/959,796 | 2020-01-10 | ||
| US202062965748P | 2020-01-24 | 2020-01-24 | |
| US62/965,748 | 2020-01-24 | ||
| US202062968443P | 2020-01-31 | 2020-01-31 | |
| US62/968,443 | 2020-01-31 | ||
| US202062980874P | 2020-02-24 | 2020-02-24 | |
| US62/980,874 | 2020-02-24 | ||
| US202063055537P | 2020-07-23 | 2020-07-23 | |
| US63/055,537 | 2020-07-23 | ||
| US202063069066P | 2020-08-23 | 2020-08-23 | |
| US63/069,066 | 2020-08-23 | ||
| US202063132929P | 2020-12-31 | 2020-12-31 | |
| US63/132,929 | 2020-12-31 | ||
| PCT/US2021/012756 WO2021142307A1 (en) | 2020-01-10 | 2021-01-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025172493A Division JP2026012197A (ja) | 2020-01-10 | 2025-10-14 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510350A JP2023510350A (ja) | 2023-03-13 |
| JP2023510350A5 true JP2023510350A5 (cg-RX-API-DMAC7.html) | 2024-01-22 |
| JP7780691B2 JP7780691B2 (ja) | 2025-12-05 |
Family
ID=76788858
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542336A Active JP7780691B2 (ja) | 2020-01-10 | 2021-01-08 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| JP2025172493A Pending JP2026012197A (ja) | 2020-01-10 | 2025-10-14 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025172493A Pending JP2026012197A (ja) | 2020-01-10 | 2025-10-14 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230111212A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087878A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7780691B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220125802A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115335401A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021205346A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022013572A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294478A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022008540A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021142307A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US20230111212A1 (en) * | 2020-01-10 | 2023-04-13 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP4087653A4 (en) * | 2020-01-10 | 2024-06-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JPWO2022270585A1 (cg-RX-API-DMAC7.html) | 2021-06-23 | 2022-12-29 | ||
| JP2024525613A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス,インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
| CA3226301A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US20240318176A1 (en) * | 2021-07-09 | 2024-09-26 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023026994A1 (ja) * | 2021-08-21 | 2023-03-02 | 武田薬品工業株式会社 | ヒトトランスフェリンレセプター結合ペプチド-薬物コンジュゲート |
| EP4395829A1 (en) * | 2021-09-01 | 2024-07-10 | Entrada Therapeutics, Inc. | Compounds and methods for skipping exon 44 in duchenne muscular dystrophy |
| EP4395831A1 (en) * | 2021-09-01 | 2024-07-10 | Entrada Therapeutics, Inc. | Compositions and methods for skipping exon 45 in duchenne muscular dystrophy |
| IL311507A (en) * | 2021-09-16 | 2024-05-01 | Dyne Therapeutics Inc | Dosing of muscle targeting complexes for the treatment of dystrophinopathy |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| JP2026503873A (ja) * | 2022-10-31 | 2026-02-02 | ダイン セラピューティクス,インコーポレーテッド | Dmd遺伝子のエクソン45をスキップするための筋肉標的化複合体およびその使用 |
| JP2026516311A (ja) | 2023-04-24 | 2026-05-21 | バイオマリン ファーマシューティカル インコーポレイテッド | Stxbp1障害を治療するための組成物および方法 |
| CN120648680A (zh) * | 2024-03-15 | 2025-09-16 | 迦进生物医药(上海)有限公司 | 治疗杜兴型肌营养不良症和贝克型肌营养不良症的药物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| ES2283759T3 (es) * | 2002-01-18 | 2007-11-01 | Pierre Fabre Medicament | Anticuerpos anti-igf-ir y sus aplicaciones. |
| EP2427554B1 (en) * | 2009-05-08 | 2016-11-16 | CuRNA, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
| EP2658574A4 (en) * | 2010-12-30 | 2014-03-12 | Cedars Sinai Medical Center | NANOBIOPOLYMER COMPOSITIONS BASED ON POLYEPELIC ACID BASE AND METHOD FOR THE TREATMENT OF CANCER |
| CN104520324A (zh) * | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
| JP6779876B2 (ja) * | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| KR20240172236A (ko) * | 2017-01-06 | 2024-12-09 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
| CN118638787A (zh) * | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| IL312067B2 (en) * | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
| WO2021142331A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
| JP7858532B2 (ja) * | 2020-01-10 | 2026-05-14 | ダイン セラピューティクス,インコーポレーテッド | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
| WO2021142260A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of acvr1 |
| WO2021142269A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
| CN115427448A (zh) * | 2020-01-10 | 2022-12-02 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| EP4087653A4 (en) * | 2020-01-10 | 2024-06-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20230111212A1 (en) * | 2020-01-10 | 2023-04-13 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CN122124274A (zh) * | 2020-01-10 | 2026-06-02 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途 |
| WO2021142217A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Thereapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of milck1 |
| IL295022A (en) * | 2020-01-31 | 2022-09-01 | Dyne Therapeutics Inc | Antibody against transferrin receptor and uses thereof |
| JPWO2022270585A1 (cg-RX-API-DMAC7.html) * | 2021-06-23 | 2022-12-29 |
-
2021
- 2021-01-08 US US17/791,701 patent/US20230111212A1/en active Pending
- 2021-01-08 BR BR112022013572A patent/BR112022013572A2/pt unknown
- 2021-01-08 AU AU2021205346A patent/AU2021205346A1/en active Pending
- 2021-01-08 KR KR1020227027138A patent/KR20220125802A/ko active Pending
- 2021-01-08 MX MX2022008540A patent/MX2022008540A/es unknown
- 2021-01-08 JP JP2022542336A patent/JP7780691B2/ja active Active
- 2021-01-08 EP EP21738534.3A patent/EP4087878A4/en active Pending
- 2021-01-08 IL IL294478A patent/IL294478A/en unknown
- 2021-01-08 CN CN202180019467.9A patent/CN115335401A/zh active Pending
- 2021-01-08 WO PCT/US2021/012756 patent/WO2021142307A1/en not_active Ceased
-
2025
- 2025-10-14 JP JP2025172493A patent/JP2026012197A/ja active Pending